The MOMENTUM study found 27 percent of patients with resistant hypertension have hypercortisolism. This is a significant finding, demonstrating that hypercortisolism is more common in these patients ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

To the mind of Sean Maduck, president of Corcept Endocrinology, the target audience of patients at the center of its recent direct-to-consumer (DTC) marketing push often go through 10-plus doctors ...

In a trial, relacorilant significantly reduced the likelihood of hypertension response loss among patients with endogenous hypercortisolism.

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and hypercortisolism, a randomized placebo-controlled trial showed. Among 136 patients, ...

At the recent American Association of Clinical Endocrinology (AACE) annual meeting, experts highlighted new approaches to identifying and managing hypercortisolism in patients with type 2 diabetes, ...

Corcept Therapeutics CORT announced that the FDA has issued a complete response letter (“CRL”) to its new drug application (“NDA”), seeking approval for its proprietary, selective cortisol modulator, ...

Please provide your email address to receive an email when new articles are posted on . The percentage of adults with hypercortisolism and difficult-to-control type 2 diabetes was higher than ...

Please provide your email address to receive an email when new articles are posted on . “Our findings are important because they add to the previously scant information about adrenal incidentalomas, ...

ORLANDO, Florida — Almost a quarter of patients with poorly controlled type 2 diabetes enrolled in the prevalence-phase of a new study had hypercortisolism, suggesting there may need to be a shift in ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

Management reaffirmed revenue guidance of $900 million to $950 million for 2025, incorporating expected growth in Korlym volumes and the shift towards its authorized generic version. Sean Maduck ...